Previous 10 | Next 10 |
Safety First: NASCAR driver Johanna Long and her helmet (Credit: Gearheads ) Bulletproof Investing: Week 72 Performance Each week since the beginning of June 2017, I have presented at least two hedged portfolios created by Portfolio Armor to my Bulletproof Investing subscribers. This is...
Pacira BioSciences (NASDAQ: PCRX ) has finalized its merger with privately held MyoScience. More news on: Pacira Pharmaceuticals, Inc., Healthcare stocks news, Merger & acquisition news, Read more ...
-- Adds highly complementary cryoanalgesia treatment to commercial offering -- -- New corporate name of Pacira BioSciences reflects expanding product portfolio -- PARSIPPANY, N.J., April 09, 2019 (GLOBE NEWSWIRE) -- Pacira BioSciences, Inc. (“Pacira”) (NASDAQ: P...
Our weekend preview of upcoming IPOs, earnings reports, conference presentations, investor days, IPO lockup expirations, FDA decisions, Barron's mentions and other key events that could impact stocks. If you are interested in listening to Stocks To Watch to start your Sunday (you c...
Welcome to Seeking Alpha's Stocks to Watch - a preview of key events scheduled for the next week. Follow this account and turn the e-mail alert on to receive this article in your inbox every Saturday morning. The week ahead sees a heavy dose of healthcare companies presenting at investor con...
PARSIPPANY, N.J., April 02, 2019 (GLOBE NEWSWIRE) -- Pacira Pharmaceuticals, Inc. (NASDAQ: PCRX) today reported that it will present at the 18 th Annual Needham Healthcare Conference at 3:30 PM ET on Tuesday, April 9, 2019. Live audio of the presentation can be accessed by visiting the...
(Rendition of Brain Neurons, Source: NIH) The biotech sector has continued to participate in the market rally. One of the reasons is the strength in biopharma M&A activity, which provides unique support for valuations and particularly assists the small-and-midcap biotech companies. We ...
Pacira Pharmaceuticals ( PCRX ) recently acquired MyoScience which markets the Iovera system, an FDA approved non-opioid treatment for pain using focused cold therapy, notes biotech expert John McCamant , editor of The Medical Technology Stock Letter . Pacira will make an initial p...
PARSIPPANY, N.J., March 13, 2019 (GLOBE NEWSWIRE) -- Pacira Pharmaceuticals, Inc. (NASDAQ: PCRX) today announced new data showing that a patient-optimizing, opioid-sparing enhanced recovery after surgery (ERAS) pathway, which includes intraoperative infiltration with EXPAREL ® (bu...
-- Novel cryoanalgesia treatment highly complementary to EXPAREL -- -- Corporate name change to Pacira BioSciences to reflect expanding product portfolio -- -- Conference call today at 8:30 AM ET -- PARSIPPANY, N.J. and FREMONT, Calif., March 05, 2019 (GLOBE NEWSWIRE) -- Paci...
News, Short Squeeze, Breakout and More Instantly...
Pacira BioSciences Inc. Company Name:
PCRX Stock Symbol:
NASDAQ Market:
Pacira BioSciences Inc. Website:
-- Proposed Hospital Outpatient Prospective Payment and Ambulatory Surgical Center Payment System Rule extends separate payment from ambulatory surgical centers to include the hospital outpatient environment – -- Rule implements the NOPAIN Act, signed into law as part of the Cons...
A look at the top 10 most actives in the United States Ocean Power Technologies Inc. (OPTT) rose 86.1% to $0.514 on volume of 587,366,807 shares NVIDIA Corporation (NVDA) fell 1.3% to $122.67 on volume of 214,038,378 shares Tesla Inc. (TSLA) rose 10.2% to $231.26 on volume of 201,850,947 ...
2024-07-02 14:00:06 ET Oren Livnat from H.C. Wainwright issued a price target of $57.00 for PCRX on 2024-07-02 12:36:00. The adjusted price target was set to $57.00. At the time of the announcement, PCRX was trading at $21.91. The overall price target consensus is at $48...